AR099960A1 - Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria - Google Patents
Procedimientos y composición farmaceutica para inducir una respuesta inmunitariaInfo
- Publication number
- AR099960A1 AR099960A1 ARP150101025A ARP150101025A AR099960A1 AR 099960 A1 AR099960 A1 AR 099960A1 AR P150101025 A ARP150101025 A AR P150101025A AR P150101025 A ARP150101025 A AR P150101025A AR 099960 A1 AR099960 A1 AR 099960A1
- Authority
- AR
- Argentina
- Prior art keywords
- common
- adjuvant
- composition
- antigen
- rts
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- 230000028993 immune response Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 16
- 239000002671 adjuvant Substances 0.000 abstract 11
- 239000000427 antigen Substances 0.000 abstract 8
- 102000036639 antigens Human genes 0.000 abstract 8
- 108091007433 antigens Proteins 0.000 abstract 8
- 230000002163 immunogen Effects 0.000 abstract 6
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 239000007764 o/w emulsion Substances 0.000 abstract 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 2
- 229930182490 saponin Natural products 0.000 abstract 2
- 150000007949 saponins Chemical class 0.000 abstract 2
- 101710117490 Circumsporozoite protein Proteins 0.000 abstract 1
- 241000224016 Plasmodium Species 0.000 abstract 1
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 241000223810 Plasmodium vivax Species 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1405921.6A GB201405921D0 (en) | 2014-04-02 | 2014-04-02 | Novel methods for inducing an immune response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099960A1 true AR099960A1 (es) | 2016-08-31 |
Family
ID=50737873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101025A AR099960A1 (es) | 2014-04-02 | 2015-04-06 | Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10624961B2 (enExample) |
| EP (2) | EP3125929B8 (enExample) |
| JP (2) | JP6655549B2 (enExample) |
| KR (2) | KR20160132115A (enExample) |
| CN (2) | CN106456738B (enExample) |
| AR (1) | AR099960A1 (enExample) |
| AU (1) | AU2015239025B2 (enExample) |
| BE (1) | BE1022355B1 (enExample) |
| BR (2) | BR112016022787A2 (enExample) |
| CA (2) | CA2943007C (enExample) |
| EA (1) | EA037405B1 (enExample) |
| ES (2) | ES2853773T3 (enExample) |
| GB (1) | GB201405921D0 (enExample) |
| IL (1) | IL247493B (enExample) |
| MX (3) | MX2016012982A (enExample) |
| SG (1) | SG11201607086QA (enExample) |
| WO (2) | WO2015150567A1 (enExample) |
| ZA (1) | ZA201605955B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| GB201621686D0 (en) * | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| GB2577232B (en) | 2017-05-30 | 2022-07-06 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
| WO2019106192A1 (en) | 2017-12-01 | 2019-06-06 | Glaxosmithkline Biologicals Sa | Saponin purification |
| CA3142300C (en) | 2019-06-05 | 2025-02-04 | Glaxosmithkline Biologicals Sa | SAPONIN PURIFICATION |
| CN112198318B (zh) * | 2020-07-15 | 2021-07-20 | 南京岚煜生物科技有限公司 | 抗体标准品赋值和抗体检测试剂最低检出限确定的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US152200A (en) * | 1874-06-16 | Improvement in garters | ||
| US1002607A (en) * | 1905-08-28 | 1911-09-05 | John Willard Taylor | Paper pulley. |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| NZ539509A (en) | 2002-10-23 | 2008-05-30 | Glaxosmithkline Biolog Sa | Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine |
| AU2005293572B2 (en) | 2004-10-14 | 2011-08-04 | Crucell Holland B.V. | Malaria prime/boost vaccines |
| CA2607715C (en) * | 2005-04-29 | 2015-11-24 | Glaxosmithkline Biologicals S.A. | Novel method for preventing or treating m tuberculosis infection |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| EP2087128A4 (en) * | 2006-11-01 | 2009-11-04 | Immport Therapeutics Inc | COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES |
| EA021391B1 (ru) * | 2007-03-02 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор |
| PE20090146A1 (es) * | 2007-04-20 | 2009-03-23 | Glaxosmithkline Biolog Sa | Composicion inmunogenica contra el virus influenza |
| US20110206712A1 (en) * | 2008-07-25 | 2011-08-25 | James Brown | Tuberculosis rv2386c protein, compositions and uses thereof |
| HUE037121T2 (hu) * | 2008-07-25 | 2018-08-28 | Glaxosmithkline Biologicals Sa | Új készítmények és eljárások |
| CA2731499C (en) * | 2008-07-25 | 2017-01-10 | Glaxosmithkline Biologicals S.A. | Composition and use thereof for treating or preventing latent tuberculosis |
| HUE031184T2 (en) * | 2010-01-27 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Modified tuberculosis antigens |
| JP5951633B2 (ja) * | 2010-12-14 | 2016-07-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | マイコバクテリウム抗原性組成物 |
| WO2015126930A2 (en) * | 2014-02-18 | 2015-08-27 | Stc.Unm | Booster drug therapy for mycobacterium infections |
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| CN106232138A (zh) * | 2014-04-24 | 2016-12-14 | 国家血清研究所 | 新型结核分枝杆菌疫苗 |
| GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
-
2014
- 2014-04-02 GB GBGB1405921.6A patent/GB201405921D0/en not_active Ceased
-
2015
- 2015-04-02 US US15/300,338 patent/US10624961B2/en active Active
- 2015-04-02 US US15/300,852 patent/US10688168B2/en active Active
- 2015-04-02 EA EA201691638A patent/EA037405B1/ru not_active IP Right Cessation
- 2015-04-02 EP EP15713532.8A patent/EP3125929B8/en active Active
- 2015-04-02 JP JP2016560336A patent/JP6655549B2/ja not_active Expired - Fee Related
- 2015-04-02 WO PCT/EP2015/057423 patent/WO2015150567A1/en not_active Ceased
- 2015-04-02 EP EP15713531.0A patent/EP3125930B1/en active Active
- 2015-04-02 AU AU2015239025A patent/AU2015239025B2/en active Active
- 2015-04-02 CN CN201580016665.4A patent/CN106456738B/zh active Active
- 2015-04-02 ES ES15713531T patent/ES2853773T3/es active Active
- 2015-04-02 CN CN201580030331.2A patent/CN106456739A/zh active Pending
- 2015-04-02 ES ES15713532T patent/ES2961840T3/es active Active
- 2015-04-02 BR BR112016022787-5A patent/BR112016022787A2/pt not_active Application Discontinuation
- 2015-04-02 KR KR1020167029523A patent/KR20160132115A/ko not_active Ceased
- 2015-04-02 JP JP2016559965A patent/JP6645982B2/ja active Active
- 2015-04-02 KR KR1020237017095A patent/KR102762440B1/ko active Active
- 2015-04-02 BE BE2015/5209A patent/BE1022355B1/fr not_active IP Right Cessation
- 2015-04-02 IL IL247493A patent/IL247493B/en unknown
- 2015-04-02 SG SG11201607086QA patent/SG11201607086QA/en unknown
- 2015-04-02 WO PCT/EP2015/057424 patent/WO2015150568A1/en not_active Ceased
- 2015-04-02 BR BR112016022463A patent/BR112016022463A2/pt not_active Application Discontinuation
- 2015-04-02 CA CA2943007A patent/CA2943007C/en active Active
- 2015-04-02 CA CA2943711A patent/CA2943711A1/en not_active Abandoned
- 2015-04-02 MX MX2016012982A patent/MX2016012982A/es unknown
- 2015-04-02 MX MX2016012932A patent/MX2016012932A/es unknown
- 2015-04-06 AR ARP150101025A patent/AR099960A1/es unknown
-
2016
- 2016-08-26 ZA ZA2016/05955A patent/ZA201605955B/en unknown
- 2016-09-30 MX MX2022013912A patent/MX2022013912A/es unknown
-
2020
- 2020-03-11 US US16/815,635 patent/US11951161B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099960A1 (es) | Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria | |
| CL2019003264A1 (es) | Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151) | |
| BR112016015422A2 (pt) | formulações de vacina de frasco único | |
| MX2016004063A (es) | Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta. | |
| MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
| EA201791907A1 (ru) | Бивалентная вакцина против вируса свиного гриппа | |
| AR102547A1 (es) | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso | |
| EA201790507A1 (ru) | Способы и композиции для усиления иммунных ответов | |
| MX392862B (es) | Formulación de vacuna contra el vih. | |
| AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
| PH12015501716B1 (en) | Anti-mycoplasma spp. subunit vaccine | |
| WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
| CO2018010874A2 (es) | Vacuna de virus de zika atenuado vivo | |
| BR112017028212A2 (pt) | vacinação concomitante contra dengue e febre amarela | |
| BR112017022755A2 (pt) | formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual | |
| AR104271A1 (es) | Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante | |
| BR112014023283A8 (pt) | Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza | |
| EA201792314A1 (ru) | Фармацевтическая комбинация эверолимуса и дактолисиба | |
| MX388527B (es) | Composiciones adyuvantes y metodos relacionados. | |
| AR106501A1 (es) | Adyuvante y composición de vacuna que lo contiene | |
| BR112014012184A2 (pt) | vacina de malária | |
| PH12022550081A1 (en) | Ehrlichia vaccines and immunogenic compositions | |
| BR112017028052A2 (pt) | peptídeo, método para induzir uma resposta imune em um sujeito e formulação de vacina | |
| ES2424831B1 (es) | Adyuvante inmnulógico para la formulación de vacunas y vacuna frente a Leishmaniasis que lo comprende | |
| AR094912A1 (es) | Vacuna contra el virus de la leucemia bovina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |